AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer
An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.
PR Newswire·